Consun Pharmaceutical Group Limited

HKSE 1681.HK

Consun Pharmaceutical Group Limited Net Income Margin for the year ending December 31, 2023: 30.29%

Consun Pharmaceutical Group Limited Net Income Margin is 30.29% for the year ending December 31, 2023, a 3.77% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.
  • Consun Pharmaceutical Group Limited Net Income Margin for the year ending December 31, 2022 was 29.19%, a 1.12% change year over year.
  • Consun Pharmaceutical Group Limited Net Income Margin for the year ending December 31, 2021 was 28.86%, a 1.43% change year over year.
  • Consun Pharmaceutical Group Limited Net Income Margin for the year ending December 31, 2020 was 28.46%, a 516.13% change year over year.
  • Consun Pharmaceutical Group Limited Net Income Margin for the year ending December 31, 2019 was 4.62%, a -81.70% change year over year.
Key data
Date Net Income Margin EBITDA Margin EBIT Margin EBITDA
Market news
Loading...
SV Wall Street
HKSE: 1681.HK

Consun Pharmaceutical Group Limited

Description

Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography. The company also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; and Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis. In addition, it offers Gyn Antidysmenorrheic tablets for the treatment of irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion for staphylococcus aureus, Candida albicans, and escherichia coli in the feminine vaginal. Further, the company provides bone-setting liquid; Yunxiang analgesic tincture for treatment of rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; and Shiduqing capsules and tablets, and Paeonol ointment for skin disease. Additionally, it offers hepatobiliary, gastroenterology, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.

Similar companies

1666.HK

Tong Ren Tang Technologies Co. Ltd.

USD 0.64

0.44%

1515.HK

China Resources Medical Holdings Company Limited

USD 0.51

0.29%

StockViz Staff

February 8, 2025

Any question? Send us an email